How does anticoagulant therapy impact systemic embolism risks in hypertrophic cardiomyopathy, and what protocols ensure optimal management?
Gaurav ChauhanContributor
How does anticoagulant therapy influence systemic embolism risk in hypertrophic cardiomyopathy?
Share
Anticoagulant therapy reduces the risk of systemic embolism in hypertrophic cardiomyopathy by preventing blood clot formation. Optimal management includes regular monitoring of INR levels and adjusting dosages as necessary.